Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc. BLUEV


Primary Symbol: BLUE

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.


Recent & Breaking News (NDAQ:BLUE)

bluebird bio Receives EC Approval for SKYSONA(TM) (elivaldogene autotemcel, Lenti-D(TM)) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor

Business Wire July 21, 2021

bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO(TM) Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU

Business Wire July 9, 2021

BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

Business Wire June 11, 2021

betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for ?-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual

Business Wire June 11, 2021

bluebird bio to Present at Goldman Sachs Global Healthcare Conference

Business Wire June 7, 2021

bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and ?-Thalassemia Studies

Business Wire June 7, 2021

bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 2, 2021

bluebird bio Receives Positive CHMP Opinion for SKYSONA(TM) (elivaldogene autotemcel, Lenti-D(TM)) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)

Business Wire May 21, 2021

Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio's Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma

Business Wire May 19, 2021

bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress

Business Wire May 13, 2021

bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress

Business Wire May 5, 2021

bluebird bio Announces May Investor Events

Business Wire May 3, 2021

bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations

Business Wire April 20, 2021

BLUE Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio, Inc. Investors of Class Action and Lead Plaintiff Deadline April 13, 2021

ACCESSWIRE IA April 13, 2021

BlueBird Bio, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

GlobeNewswire April 13, 2021

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile April 13, 2021

Final Deadline Today: Rosen, National Trial Counsel, Encourages bluebird bio, Inc. Investors with Losses to Secure Counsel Before Important April 13 Deadline in Securities Class Action - BLUE

Newsfile April 13, 2021

BLUE Final Deadline Today: Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio, Inc. Investors of Class Action and Lead Plaintiff Deadline April 13, 2021

Newsfile April 13, 2021

FINAL DEADLINE APRIL 13: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA April 13, 2021

BLUE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 13, 2021 in the Class Action Filed on Behalf of bluebird bio, Inc. Limited Shareholders

Newsfile April 12, 2021